IMAX · Imax Corp · Stock research

Current Thesis

IMAX is the listed toll booth on premium theatrical: it does not own the films and largely does not own the theatres, it licenses the format and takes a cut of the gross. The 2026-07-23 Q2 print put hard numbers under that model — revenue $102.8M against $93.746M consensus, adjusted EPS $0.43 against $0.28, adjusted EBITDA margin 46.6% — and the stock gapped roughly 11–12% on the day. CNBC reported on 2026-08-03 that July 2026 was the highest-grossing month in the company's 50-plus-year history at $257M, driven by Universal's The Odyssey, the fastest title ever to $200M in global IMAX box office. That is the narrative leg on offer: a fixed-cost network monetising somebody else's blockbuster at 46%-plus incremental margin.

The complication is timing. Price closed at $48.49 on 2026-08-07, 5.4% under the $51.26 52-week high, with RSI(14) at 74.5 after a 37.4% three-month advance. The six price targets published on 2026-07-24 run $45 to $54 — the consensus band sits on top of spot. And there is no company-reported datapoint until the Q3 release around late October.

Bullish and bearish views on Imax Corp

The model's bull view on Imax Corp (IMAX), in brief: Q2 2026 (2026-07-23): revenue $102.8M vs $93.746M consensus (+12% YoY); adjusted EPS $0.43 vs $0.28 consensus (+65% YoY); adjusted EBITDA margin 46.6%. The bear view: Guidance was maintained, not raised. On 2026-07-23 the company held FY2026 at approximately $1.4B global box office, 160–175 installations and mid-40% total adjusted EBITDA margin with a 45% floor — after the quarter that produced a record July. Either the guide is conservative… Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-23): revenue $102.8M vs $93.746M consensus (+12% YoY); adjusted EPS $0.43 vs $0.28 consensus (+65% YoY); adjusted EBITDA margin 46.6%.
• Network build is at a decade high: 38 systems installed in Q2 2026, the strongest Q2 in ten years, against a backlog of 421 systems (263 new, 158 upgrades) — a visible multi-year installation pipeline rather than a one-quarter surge.
• Scale of the footprint: 1,809-plus locations in 91 countries as of Q2 2026, with the company claiming over half of global premium-cinema locations. Incremental box office runs through a network whose cost base is already built.
• July 2026 set a company record: $257M, the highest-grossing month in IMAX history (CNBC, 2026-08-03). The Odyssey took $44M in its third IMAX weekend and opened at $52M globally in IMAX.
• Sell-side moved as a block on 2026-07-24: Wedbush to $54 (Outperform), B. Riley to $52 (Buy), JP Morgan to $50 (Overweight), Roth to $50 (Buy), Rosenblatt to $50 (Buy), Wells Fargo to $45 (Equal-Weight).
• The December window is already booked: Dune: Part Three has locked roughly 400 IMAX screens with domestic IMAX exclusivity for its first three weeks from 2026-12-18, with tickets on sale months ahead. Avengers: Doomsday opens the same day without US IMAX screens in that window.
• International network additions continue: on 2026-07-21 IMAX and CGV extended their partnership to upgrade three existing Vietnam locations to IMAX with Laser starting 2027.

Bear Case

• Guidance was maintained, not raised. On 2026-07-23 the company held FY2026 at approximately $1.4B global box office, 160–175 installations and mid-40% total adjusted EBITDA margin with a 45% floor — after the quarter that produced a record July. Either the guide is conservative or the back half is thinner than the tape implies; the Q3 print is where that resolves.
• The published targets are already here. A $45–$54 band set on 2026-07-24 against a $48.49 close on 2026-08-07 leaves the highest street number roughly 11% above spot and the lowest below it.
• December is one title deep domestically. The three-week exclusivity that makes Dune: Part Three a bull point also removes the fallback: Avengers: Doomsday is not in US IMAX during that window, so a soft Dune opening has no domestic substitute on those screens.
• Slate risk is not company risk. Revenue timing is set by Warner Bros., Universal and Disney release calendars. A date move at a studio moves IMAX's quarter without anything changing inside IMAX.
• Catalyst vacuum. Between the 2026-07-23 print and the Q3 report around 2026-10-22 there is no scheduled company disclosure — the only inputs are weekend box-office grosses.

Setup & Price Structure

Last completed daily close $48.49 (2026-08-07). The 52-week high is $51.26, 5.4% overhead; CNBC dated the all-time high to the week of 2026-08-03, meaning the high was made and has not been reclaimed in the sessions since. Three-month return 37.4%. RSI(14) 74.5 — above the 70 line, which describes an extended tape rather than a broken one.

Crowding and positioning observables, stated as observables:

• Six price-target revisions landed inside a single session on 2026-07-24, all following the same print.
• Mainstream financial coverage arrived on 2026-08-03 with a CNBC feature quoting CEO Rich Gelfond calling the momentum a "flywheel" — general-audience coverage of a stock at an all-time high.
• That is routine-size RSU housekeeping and does not read as distribution; it is logged here because it is the only insider filing in the window.
• No earnings date inside 30 days, so the near-term flow driver is weekend box office rather than a scheduled print.

Life-cycle placement: MATURING. The acceleration phase is dated — 2026-07-23 print, 2026-07-24 target block, 2026-08-03 record-month headline. What follows is the moderating leg: the story is well known, still working on fundamentals, and the price has stalled 5.4% below its high after the mainstream write-up. The markers that would push this to SATURATED are visible but not yet confirmed: general-audience coverage has arrived, the target band brackets spot, and there is no new bid scheduled until October.

Catalyst Calendar (next 30 days)

• ~2026-08-28 (est.) — The Dog Stars opens with a reported two-week IMAX window. First meaningful IMAX-window title after The Odyssey's run; per-screen grosses show whether the network holds up on a non-event title.
• Weekends of 2026-08-14/16 and 2026-08-21/23 — weekend box-office reporting. The Odyssey holdover economics and the Sony Spider-Man: Brand New Day IMAX expansion that began 2026-08-06 are the observable inputs; these are the only high-frequency data between now and October.
• ~2026-09-17 (est.) — Resident Evil theatrical release (just outside the 30-day window; listed because it is the next slate anchor).
• No scheduled company disclosure inside 30 days. The next one is the Q3 2026 report, estimated ~2026-10-22 based on prior-year cadence.

What Would Change Our Mind

The load-bearing beam is the December window. If Warner Bros. Moves the 2026-12-18 Dune: Part Three date, or the three-week domestic IMAX exclusivity is shortened or shared, the single largest identified Q4 event for the network loses its shape and the ~$1.4B FY global box-office guide has to be carried by a slate that has not yet been tested.

The second thing that would change the read is a Q3 report around 2026-10-22 that reiterates $1.4B rather than raising it. A record July that does not move the annual number implies the back half is being consumed by guidance rather than adding to it.

On price, the gradeable break: a weekly close below $44 unwinds the advance built off the 2026-07-23 print and takes out the August structure. A second, slower condition is the $51.26 52-week high going unrecovered through September — that combination would date the narrative's roll from MATURING to SATURATED without needing a single fundamental to miss.

Conversely, a Q3 raise above $1.4B with installations tracking to the upper half of 160–175 would extend the leg rather than break it.

Correlation Notes

• Exhibitors (CNK, AMC): IMAX shares the box-office input but not the cost structure — it collects a royalty on gross rather than operating the auditoriums, so the beta is to industry box office with the operating leverage of a licensor. The Q2 combination of +12% revenue and a 46.6% adjusted EBITDA margin is the arithmetic of that difference.
• Studios: for Q4 2026 specifically, the domestic IMAX network is a Warner Bros./Legendary slate proxy, not a Disney/Marvel one, because Avengers: Doomsday has no US IMAX screens in its first three weeks from 2026-12-18. That is an unusual, dated decoupling from the normal Marvel-drives-premium-format relationship.
• Comcast/Universal: The Odyssey is the Universal title behind the record $257M July, so IMAX's H2 2026 comparisons will be measured against a Comcast-distributed film.
• China and international: with 1,809-plus locations across 91 countries, the network carries international box-office and FX exposure that does not show up in a US-only box-office print.
• Consumer discretionary: out-of-home entertainment spend is the underlying demand series; IMAX's premium pricing means it is levered to the willingness to pay up for a format, which historically decouples from ticket volume.